穴位療法治療哮病的臨床效果及機(jī)制(1)
摘要 目的：探討穴位療法對(duì)哮病緩解期患者臨床療效的機(jī)制。方法：選取2015年1月至2016年6月武漢市第一醫(yī)院收治的哮病緩解期患者90例，按隨機(jī)數(shù)字表分為A組、B組、C組，每組30例，A組給予穴位療法，B組給予穴位注射，C組給予舒利迭治療，共治療8周。觀察3組患者治療2個(gè)月后(近期)和停止治療3個(gè)月后(遠(yuǎn)期)的哮喘控制情況(完全控制、部分控制、未控制)以及患者治療前、治療2個(gè)月后(近期)、停止治療3個(gè)月后(遠(yuǎn)期)的皮質(zhì)醇(COR)、T淋巴細(xì)胞亞群(CD4+、CD8+、CD4+/CD8+)、白介素5(IL-5)、白介素10(IL-10)的水平，并對(duì)3組近遠(yuǎn)期療效及COR、CD4+、CD8+、CD4+/CD8+、IL-5、IL-10)的水平進(jìn)行統(tǒng)計(jì)學(xué)分析。結(jié)果：3組近期療效，A組治療有效率(96.67%)明顯優(yōu)于B組(80.00%)和C組(66.67%)(P<0.05)，差異有統(tǒng)計(jì)學(xué)意義；3組遠(yuǎn)期療效，A組治療有效率(93.33%)明顯優(yōu)于B組(76.67%)和C組(63.33%)(P<0.05)，差異有統(tǒng)計(jì)學(xué)意義；A組治療2個(gè)月后和停止治療3個(gè)月后的COR、CD4+、CD8+、CD4+/CD8+、IL-5、IL-10的水平與B組、C組同期比較，均有明顯改善，差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論：穴位療法通過補(bǔ)腎、健脾、通肺氣可能改善哮病患者COR、CD4+、CD8+、CD4+/CD8+、IL-5、IL-10水平的變化，從而提高臨床療效。
, http://www.www.srpcoatings.com
關(guān)鍵詞 穴位療法；哮病；皮質(zhì)醇；T淋巴細(xì)胞亞群；白介素
Abstract Objective：To explore the clinical effect mechanism of acupoint therapy in patients with asthma at remission stage. Methods：A total of 90 patients with asthma at remission stage who were admitted and treated in Wuhan First Hospital from January 2015 to June 2016 were selected and divided into group A (acupoint therapy)， group B (acupoint injection) and group C (seretide) according to the random number table with 30 cases in each group. The treatment last 8 weeks. The asthma control situation (full control， portion control， no control) after two months′ treatment (short-term) and 3 months after stopping treatment (long-term)， and cortisol (COR)， Interleukin-5 (IL-5)， Interleukin-10 (IL-10)， T lymphocytes (CD4+， CD8+， CD4+/CD8+) before treatment， after two months′ treatment (short-term) and 3 months after stopping treatment (long-term) of patients in three groups were observed， and clinical efficacy in short-term and long-term， as well as the levels of COR， CD4+， CD8+， CD4+/CD8+， IL-5 and IL-10 in the three groups were statistically analyzed. Results：In short-term efficacy， the total effective rate of group A (96.67%) was significantly better than group B (80.00%) and group C (66.67%) with statistical significance (P<0.05)； In long-term efficacy， the total effective rate of group A (93.33%) was significantly better than group B (76.67%) and group C (63.33 %) with statistical significance (P<0.05)； Compared with group B and group C， the levels of COR， CD4+， CD8+， CD4+/CD8+， IL-5 and IL-10 in group A were significantly improved with statistical significance (P<0.05). Conclusion：Acupoint therapy may improve the changes of COR， CD4+， CD8+， CD4+/CD8+， IL-5， IL-10 in patients with asthma by supplementing the kidney， strengthening the spleen and smoothing the lungs， so as to improve the clinical curative effect., 百拇醫(yī)藥(梁亞光 李斌 謝俊剛 尹瑩 羅光偉 賈珉 莫松雅 黃白銀)
, http://www.www.srpcoatings.com
關(guān)鍵詞 穴位療法；哮病；皮質(zhì)醇；T淋巴細(xì)胞亞群；白介素
Abstract Objective：To explore the clinical effect mechanism of acupoint therapy in patients with asthma at remission stage. Methods：A total of 90 patients with asthma at remission stage who were admitted and treated in Wuhan First Hospital from January 2015 to June 2016 were selected and divided into group A (acupoint therapy)， group B (acupoint injection) and group C (seretide) according to the random number table with 30 cases in each group. The treatment last 8 weeks. The asthma control situation (full control， portion control， no control) after two months′ treatment (short-term) and 3 months after stopping treatment (long-term)， and cortisol (COR)， Interleukin-5 (IL-5)， Interleukin-10 (IL-10)， T lymphocytes (CD4+， CD8+， CD4+/CD8+) before treatment， after two months′ treatment (short-term) and 3 months after stopping treatment (long-term) of patients in three groups were observed， and clinical efficacy in short-term and long-term， as well as the levels of COR， CD4+， CD8+， CD4+/CD8+， IL-5 and IL-10 in the three groups were statistically analyzed. Results：In short-term efficacy， the total effective rate of group A (96.67%) was significantly better than group B (80.00%) and group C (66.67%) with statistical significance (P<0.05)； In long-term efficacy， the total effective rate of group A (93.33%) was significantly better than group B (76.67%) and group C (63.33 %) with statistical significance (P<0.05)； Compared with group B and group C， the levels of COR， CD4+， CD8+， CD4+/CD8+， IL-5 and IL-10 in group A were significantly improved with statistical significance (P<0.05). Conclusion：Acupoint therapy may improve the changes of COR， CD4+， CD8+， CD4+/CD8+， IL-5， IL-10 in patients with asthma by supplementing the kidney， strengthening the spleen and smoothing the lungs， so as to improve the clinical curative effect., 百拇醫(yī)藥(梁亞光 李斌 謝俊剛 尹瑩 羅光偉 賈珉 莫松雅 黃白銀)
參見：首頁 > 醫(yī)療版 > 癥狀 > X > 哮病